

Centers for Disease Control and Prevention  
 1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium  
 Atlanta, Georgia 30329  
 February 21-22, 2018

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
<b><u>Wednesday, February 21</u></b>		
<b>8:00 Welcome &amp; Introductions</b>		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
<b>8:30 Hepatitis Vaccines</b>		
Introduction		Dr. Jose Romero (ACIP, WG Chair)
Review of GRADE (HEPLISAV-B)	Information	Dr. Aaron Harris (CDC/NCHHSTP)
Considerations and proposed recommendations	& Discussion	Dr. Sarah Schillie (CDC/NCHHSTP)
Public comment		
Vote	<u>Vote</u>	Dr. Sarah Schillie (CDC/NCHHSTP)
Hepatitis A post-exposure prophylaxis GRADE	Information	Dr. Noele Nelson (CDC/NCHHSTP)
Considerations and proposed recommendations	& Discussion	Dr. Noele Nelson (CDC/NCHHSTP)
Public comment		
Vote	<u>Vote</u>	Dr. Noele Nelson (CDC/NCHHSTP)
<b>10:15 Break</b>		
<b>10:30 Influenza Vaccines</b>		
Introduction		Dr. Chip Walter (ACIP, WG Chair)
Fluarix Quadrivalent: efficacy in children 6-35 months of age		Dr. Leonard Friedland (GSK)
Surveillance update		Ms. Lynnette Brammer (CDC/NCIRD)
VE update	Information	Dr. Brendan Flannery (CDC/NCIRD)
Results of a randomized trial of a new H1N1 LAIV strain in US children	& Discussion	Dr. Raburn Mallory (MedImmune/AstraZeneca)
Review of LAIV for 2 through 17 year olds		Dr. Lisa Grohskopf (CDC/NCIRD), Dr. Jill Ferdinands (CDC/NCIRD)
Considerations and proposed recommendations		Dr. Lisa Grohskopf (CDC/NCIRD)
Public comment		
Vote	<u>Vote</u>	Dr. Lisa Grohskopf (CDC/NCIRD)
VFC Vote	<u>VFC Vote</u>	Dr. Jeanne Santoli
<b>12:45 Lunch</b>		
<b>1:45 Evidence Based Recommendations</b>		
Introduction	Information	Dr. Grace Lee (ACIP, WG Chair)
Evidence to Recommendations Framework	& Discussion	Dr. Wendy Carr (CDC/NCIRD)
Public comment		
Vote	<u>Vote</u>	Dr. Wendy Carr (CDC/NCIRD)
<b>2:30 Anthrax</b>		
Introduction		Dr. David Stephens (ACIP, WG Chair)
Update on IM route of administration of vaccine	Information	Dr. William Bower (CDC/NCEZID)
Dose-sparing strategies when demand for vaccine excess	& Discussion	Dr. William Bower (CDC/NCEZID)
Duration of antimicrobial component of PEP when used in combination with anthrax vaccine		Dr. William Bower (CDC/NCEZID)
<b>3:45 Break</b>		
<b>4:00 Human Papillomavirus (HPV) Vaccines</b>		
Introduction		Dr. Peter Szilagyi (ACIP, WG Chair)
9-valent HPV vaccine safety data - VAERS update		Dr. Jorge Arana (CDC/NCEZID)
9-valent HPV vaccine rapid cycle analysis, Vaccine Safety	Information	Dr. Jim Donahue (Marshfield Clinic)
Harmonization of upper age for male and female vaccination recommendations	& Discussion	Dr. Lauri Markowitz (CDC/NCIRD)
Trends in HPV-associated cancers in the United States		Dr. Elizabeth Van Dyne, (CDC/NCCDPHP)
Epidemiology of HPV infection in males		Dr. Anil Chaturvedi (NIH/NCI)
<b>5:30 Public Comment</b>		
<b>5:45 Adjourn</b>		

**Thursday, February 22**

**8:00 Agency Updates & Unfinished Business**

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Information Dr. Nancy Messonnier (CDC/NCIRD); *Ex Officio* Members

**9:00 Pneumococcal**

Introduction  
PCV13 Effectiveness: Case Control Study  
PCV13 Direct and Indirect Effects among Adults ≥65 Year Old  
PCV13 effectiveness against pneumococcal pneumonia among U.S. Adults  
Estimating Burden of Pneumococcal Pneumonia among Adults in the U.S. Progress of the research agenda to inform potential policy change

Information & Discussion  
Dr. Grace Lee (ACIP, WG Chair)  
Dr. Tamara Pilishvili (CDC/NCIRD)  
Dr. Tamara Pilishvili (CDC/NCIRD)  
Dr. John M. McLaughlin (Pfizer Vaccines)  
Dr. Almea Matanock (CDC/NCIRD)

**10:30 Vaccines and other biologics for prevention and treatment of healthcare-associated infections**

Update

Information Dr. Anthony Fiore (CDC/NCEZID)

**11:00 Break**

**11:30 Meningococcal Disease**

Introduction  
Epidemiology of meningococcal disease among college students – United States, 2014-2016

Information & Discussion  
Dr. David Stephens (ACIP, WG Chair)  
Dr. Sarah Meyer (CDC/NCIRD)

**12:00 Japanese Encephalitis (JE) Vaccine**

Introduction  
Review of JE and work group plans

Information & Discussion  
Dr. Chip Walter (ACIP, WG Chair)  
Dr. Susan Hills (CDC/NCEZID)

**12:15 Vaccine Supply**

Information Dr. Jeanne Santoli (CDC/NCIRD)

**12:20 Public Comment**

**12:30 Adjourn**

**Acronyms**

CDC	Centers for Disease Control & Prevention
CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
JE-VC	Vero cell culture-derived Japanese encephalitis
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NCI	National Cancer Institute
NIH	National Institutes of Health
NVPO	National Vaccine Program Office
PCV13	13-valent pneumococcal conjugate vaccine
VFC	Vaccines for Children
WG	Work Group